Epithelial-mesenchymal transition and anoikis resistance induced by Ang2 in salivary adenoid cystic carcinoma

Min Zheng, Haihui Zhao, Xiaojuan Zhong, Jun Guo, Ping Zhang, Fei Wei, Yi HuangResearch Square 2024 · DOI

Introduction

Salivary Adenoid Cystic Carcinoma (SACC) is a malignant tumor characterized by slow growth but high rates of local recurrence and distant metastasis. Despite standard treatments involving surgical resection and radiotherapy, patients often face poor long-term prognoses due to the tumor's propensity for neuroinvasion and hematogenous spread, particularly to the lungs. A critical step in this metastatic cascade is the Epithelial-Mesenchymal Transition (EMT), where epithelial cells lose their polarity and cell-cell adhesion to gain migratory and invasive properties. Furthermore, for these detached cells to survive in the circulatory system, they must overcome "anoikis"—a form of programmed cell death triggered by loss of attachment to the extracellular matrix. This study investigates the role of Angiopoietin-2 (Ang2), a protein typically associated with angiogenesis, in driving both EMT and anoikis resistance in SACC.

Methods

The researchers utilized a comprehensive experimental framework to elucidate the function of Ang2:

  • Clinical Correlation: Immunohistochemical staining was performed on 31 SACC patient samples and 10 normal salivary gland tissues to evaluate Ang2 expression levels and their relationship with clinical-pathological features.
  • In Vitro Manipulation: Two SACC cell lines—SACC-83 and the highly metastatic SACC-LM—were used. Ang2 expression was silenced using short hairpin RNA (shRNA) to observe changes in cell behavior, including proliferation, migration, and colony formation.
  • Mechanistic Studies: To determine how Ang2 influences protein stability, Cycloheximide (CHX) chase assays were used to measure the half-life of the Snail protein, and the proteasome inhibitor MG132 was employed to investigate the degradation pathway.
  • In Vivo Validation: A lung metastasis model was established by injecting SACC cells into the tail veins of BALB/c mice, with metastatic nodules quantified after eight weeks.

Results

Ang2 Overexpression and Clinical Aggression

The study found that Ang2 is significantly upregulated in SACC tissues compared to normal tissues, with high expression observed in approximately 74.2% of cases. Notably, Ang2 levels were significantly higher in the "solid" histological subtype, which is associated with the most aggressive clinical behavior. High Ang2 expression also correlated with increased peripheral nerve invasion ($p = 0.0466$).

Regulation of EMT and Anoikis Resistance

Silencing Ang2 in SACC cells led to a marked reduction in migratory capacity and a shift in molecular markers: E-cadherin (an epithelial marker) was restored, while N-cadherin and Snail (mesenchymal markers) were downregulated. The researchers discovered that Ang2 promotes EMT by stabilizing the Snail protein. Specifically, Ang2 prevents the proteasome-dependent degradation of Snail, maintaining the "mesenchymal" state of the cells. Furthermore, Ang2 knockdown significantly increased apoptosis in detached cells, indicating that Ang2 is a key mediator of anoikis resistance.

Impact on Proliferation and Metastasis

In vitro, silencing Ang2 reduced the formation of highly proliferative "holoclones" by 25-30%. In vivo, the reduction of Ang2 led to a dramatic decrease in both the number and size of lung metastatic nodules in mouse models, confirming its role in facilitating distant colonization.

Discussion

This research identifies Ang2 as a dual-action oncogene in SACC, coordinating the transition to a mobile phenotype (EMT) and the survival of circulating tumor cells (anoikis resistance). While Ang2 is well-known for its role in the Tie2 signaling pathway during blood vessel formation, these findings highlight its direct intracellular role in tumor cell biology. The stabilization of Snail appears to be the central mechanism through which Ang2 exerts these effects, though the specific intermediary molecules involved in blocking Snail ubiquitination remain to be fully characterized.

Given that Ang2 expression is a hallmark of aggressive SACC subtypes and is linked to poor outcomes, it represents a promising therapeutic target. Future studies should explore the efficacy of pharmacological Ang2 inhibitors—some of which are currently in clinical trials for other indications—as a strategy to prevent metastasis in SACC patients.

Conclusion

Ang2 plays a pivotal role in the progression of Salivary Adenoid Cystic Carcinoma by inducing EMT and granting cells the ability to survive detachment. Targeting the Ang2-Snail axis offers a potential pathway for developing more effective treatments for this challenging malignancy.

Summary updated

Abstract

<title>Abstract</title> Patients, who suffer from Salivary Adenoid Cystic Carcinoma (SACC), face a heightened risk of recurrent or metastatic disease attributed to significant neuroinvasion, even with standard treatment, highlighting the imperative for innovative treatment targets and approaches. Our research indicates that the expression of angiopoietin-2 (Ang2) in the cytoplasm and nucleus of SACC tissue is significantly higher than that of normal tissue adjacent to cancer, which is related to the pathological type of the tissue. Approximately 74.2% of SACC express Ang2, which promotes survival and lung metastasis. In SACC cells, downregulation of Ang2 inhibits cell migration and enhances cell apoptosis, and resistance to cell apoptosis is deemed essential for metastasis. The downregulation of Ang2 leads to the restoration of E-cadherin levels by facilitating the proteasome-dependent degradation of its suppressor Snail.Overexpression of Snail prevented the complete inhibitory effect of Ang2 on ACC cell migration, which was in line with the promotion of epithelial mesenchymal transition (EMT). The in vivo findings demonstrated reduced lung colonization in conjunction with the downregulation of Ang2. Our findings illustrate Ang2 triggers EMT and enhances metastasis in SACC, suggesting that Ang2 could act to be a promising therapeutic option towards individuals with SACC.
BibTeX
@inproceedings{zheng2024epithelial,
  author = {Min Zheng and Haihui Zhao and Xiaojuan Zhong and Jun Guo and Ping Zhang and Fei Wei and Yi Huang},
  title = {{Epithelial-mesenchymal transition and anoikis resistance induced by Ang2 in salivary adenoid cystic carcinoma}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-4780785/v1},
}
Figure